source
- FDA again turns back Capricor Duchenne cell therapyIn an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.BioPharma Dive · 1h ago↗ source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.